CClinicalTrials.gg
Status unknownNCT05774730Updated Mar 21, 2023

Evaluation of the Effectiveness of Predicting the Integrity of Interlobar Fissures Based on Chest Image AI Technology

An observational study in Chronic Obstructive Pulmonary Disease, sponsored by China-Japan Friendship Hospital. Status unknown. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2023-03-21.

Sponsored by China-Japan Friendship Hospital · Observational

The sponsor has not verified this record recently (last verified Mar 2023), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
40
Ages
18 Years to 90 Years
Sex
All
01

Study summary

The goal of observational study is to evaluate effectiveness of predicting the integrity of interlobar fissures based on chest image AI technology in patients with Chronic Obstructive Pulmonary Disease who will undergo lung volume reduction surgery with endobronchial valve implantation. The main question it aims to answer is: evaluation of the effectiveness of predicting the integrity of interlobar fissures based on chest image AI technology.

Participants will be evaluated by lung CT (quantitative analysis based on chest image AI technology and artificial analysis) and imported Chartis detection system.

02

Conditions studied

  • Chronic Obstructive Pulmonary Disease
03

In context

Lung Diseases, Obstructive

2,592 studies on the registry are indexed under Lung Diseases, Obstructive; 198 are open to participants now.

This study's planned enrollment of 40 is below the median of 150 across 639 observational studies indexed under Lung Diseases, Obstructive.

Browse Lung Diseases, Obstructive studies →

Lead sponsor

China-Japan Friendship Hospital is the lead sponsor of 173 studies on the registry; 109 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

chronic obstructive pulmonary diseases

Inclusion criteria

  • Patients with chronic obstructive pulmonary disease who meet the GOLD diagnostic criteria
  • FEV1 ≤ 45% pred and FEV1/FVC\<70%
  • TLC>100% pred and RV>175% pred
  • CAT≥18
  • >50% of emphysema destruction
  • Smoking prohibition>6 months
  • Sign the informed consent form

Exclusion criteria

Exclusion Criteria:

  • PaCO2>8.0 kPa, or PaO2\<6.0 kPa
  • 6-minute walking test\<160m
  • Obvious chronic bronchitis, bronchiectasis or other infectious lung diseases
  • Three hospitalizations due to pulmonary infection in the past 12 months before the baseline assessment
  • Previous lobectomy, LVRS or lung transplantation
  • LVEF\<45% and or RVSP>50mmHg
  • Anticoagulant therapy that cannot be stopped before surgery
  • The patient has obvious immune deficiency
  • Participated in other lung drug studies within 30 days before this study
  • Pulmonary nodules requiring intervention
  • Any disease or condition that interferes with the completion of the initial or subsequent assessment
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • Emphysema quantitative analysis softwarebased on chest image AI technology

    Other: Emphysema quantitative analysis software based on chest image AI technology

  • artificial analysis

    Other: artificial analysis of chest image

  • imported Chartis detection system

    Procedure: imported Chartis detection system

Interventions

  • OtherEmphysema quantitative analysis software based on chest image AI technology

    The participants would undergo lung CT, and the integrity of interlobar fissure will be quantitatively analyses by software based on chest image AI technology.

  • Otherartificial analysis of chest image

    The participants would undergo lung CT, and the integrity of interlobar fissure will be artificially analyses.

  • Procedureimported Chartis detection system

    The participants would undergo imported Chartis detection system.

06

What researchers measure

Primary outcomes

  1. Therapeutic effect of lung volume reduction surgery

    Lung CT

    Time frame: 1 month after bronchoscopic valve lung volume reduction

  2. Therapeutic effect of lung volume reduction surgery

    Lung CT

    Time frame: 3 months after bronchoscopic valve lung volume reduction

  3. Therapeutic effect of lung volume reduction surgery

    Lung CT

    Time frame: 6 months after bronchoscopic valve lung volume reduction

  4. the integrity of interlobar fissure

    Emphysema quantitative analysis softwarebased on chest image AI technology, artificial analysis and imported Chartis detection system

    Time frame: Before bronchoscopic valve lung volume reduction

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05774730
Lead sponsor
China-Japan Friendship Hospital
Responsible party
Gang Hou (Principal Investigator, China-Japan Friendship Hospital) — Principal investigator
First posted
Mar 20, 2023
Start date
Mar 26, 2023 (estimated)
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Mar 21, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion